Risk arising from the lack of an established supply, sales and post-market follow-up platform for the cell-sheet regenerative medicine business

The risk that business development may be delayed because establishing the operating infrastructure for the cell sheet regenerative medicine business, including manufacturing, sales, distribution, information provision, safety measures and post-treatment follow-up, requires considerable time and expense.